My watch list  

Apeiron initiates clinical study to investigate prevention of radiation-induced skin damage in breast cancer patientes


Apeiron Biologics AG announced that a clinical trial has started with the agent superoxide dismutase (project APN201) to investigate its potential for prevention of radiation dermatitis in breast cancer patients.

Apeiron announced that a clinical trial has started with a liposomal topical formulation of the enzyme human recombinant superoxide dismutase (project APN201) at the University Hospital for Radiation Therapy / Radio-oncology of the Medical University Graz. APN201 is being developed clinically in collaboration with the Austrian contract manufacturer Polymun Scientific. The double blind, placebo-controlled study is conducted at a single center and shall enroll 20 breast cancer patients that receive radiation therapy after breast-preserving surgery.

Superoxide dismutase (SOD) is an enzyme that degrades and renders harmless highly reactive oxygen radicals that occur, amongst other situations, during radiotherapy of cancer. This pilot study aims at investigation of safety and tolerability of topical APN201 as well as hints for efficacy to prevent radiation dermatitis in breast cancer patients that undergo radiotherapy after surgery. In general, about fifty percent of cancer patients receive radiotherapy (in addition to chemotherapy, surgery and other therapies). Often, concomitant skin damage occurs which is comparable to burns. This radiation dermatitis can be severe and even lead to discontinuation of radiotherapy. Today, radiation dermatitis is mainly treated symptomatically with skin creams.

University Professor Karin Kapp, Head of the University Clinic for Radiation Therapy / Radio-oncology in Graz and principal investigator of the study: "Skin damage that may occur during radiotherapy is a severe problem for many cancer patients and can even force discontinuation of this therapy in some cases. Hence, it is of utmost clinical and scientific interest to alleviate or even prevent these side effects of radiation. It is very exciting to work on a solution for this together with Apeiron." 

Facts, background information, dossiers
More about Apeiron Biologics
  • News

    APEIRON: New CEO announced

    APEIRON Biologics AG, a Vienna based biotechnology company founded by the Austrian molecular biologist Josef Penninger, which develops immuno-oncological therapies against cancer, announced today that after almost 13 successful years Dr. Hans Loibner (70) has handed over his position as CEO ... more

    Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi

    Evotec AG and APEIRON Biologics AG announced that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. The milestone payment of EUR 3 m will be split equally between the two biotech companies. The success payment was triggered when t ... more

    Evotec, Apeiron Biologics and Sanofi develop novel cancer immunotherapies

    Evotec AG and Apeiron Biologics AG announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. This collaboration includes major research and development efforts to advance a first-in-class small molecule approach to treat solid and haematop ... more

  • Companies

    APEIRON Biologics AG

    Apeiron Biologics is engaged in the focused development of innovative therapeutics based on validated targets derived from biomedical break-through discoveries. The company, operational since 2005, was founded by Josef Penninger, a top level scientist with high international reputation and ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE